Nexalin Technology, Inc.
NXLNasdaq
$0.48
↑ +5.7%Jul 17 close · end-of-day
Price
1Y↓ -52.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.5M
Enterprise Value
$6.8M
P/E
—
P/S
34.3
P/B
3.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$275,582.00
Net Income (TTM)
-$8.3M
Free Cash Flow (TTM)
—
Gross Margin
82.0%
Operating Margin
-3084.2%
Net Margin
-3022.9%
ROE
-288.6%
ROIC
-3776.9%
Debt / Equity
—
Net Cash
$2.7M
Return 1Y
-58.5%
Company profile
We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as Generation 1 or Gen-1 — that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. We were originally formed as a Nevada corporation on October 19, 2010 as Nexalin Technology, Inc. On December 1, 2021, we completed the corporate reorganization pursuant to which Nexalin Nevada merged with and into a newly incorporated Delaware company of the same name, Nexalin and, as a result, Nexalin succeeded Nexalin Nevada and our existing shareholders exchanged each of their shares in Nexalin Nevada for one twentieth (1/20th) of a common share of the newly formed Delaware corporation. Nexalin had nominal assets and liabilities and did not conduct any operations prior to the reorganization other than its incorporation. Our principal executive offices are located at 1776 Yorktown, Suite 550, Houston, Texas.
- CEO
- Mark White
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 3
- Headquarters
- Texas
- Website
- nexalin.com
Earnings
NXL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$14,950.00↓ -63.5%
Diluted EPS-$0.11↓ -26.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $144,065.00 | $1.3M | $110,748.00 | $168,721.00 | $301,647.00 |
| Gross profit | — | $122,623.00 | $958,145.00 | $85,060.00 | $132,128.00 | $240,274.00 |
| Operating income | — | -$6.0M | -$1.8M | -$5.7M | -$7.8M | -$8.4M |
| Net income | — | -$6.1M | -$1.7M | -$4.6M | -$7.6M | -$8.2M |
| Diluted EPS | — | — | -$0.30 | -$0.63 | -$0.83 | -$0.50 |
| Operating cash flow | — | -$1.1M | -$2.2M | -$3.8M | -$3.9M | -$5.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | 85.1% | 72.5% | 76.8% | 78.3% | 79.7% |
| Operating margin | — | -4177.7% | -138.7% | -5143.5% | -4596.1% | -2781.7% |
| Net margin | — | -4218.9% | -128.5% | -4197.6% | -4508.7% | -2725.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26,840.00 | $36,031.00 | $27,179.00 | $41,015.00 | $70,588.00 | $18,149.00 | $171,895.00 | $14,950.00 |
| Gross profit | $19,593.00 | $23,337.00 | $19,683.00 | $27,457.00 | $47,750.00 | $14,201.00 | $150,866.00 | $13,133.00 |
| Operating income | -$1.3M | -$2.5M | -$2.9M | -$2.0M | -$1.6M | -$2.3M | -$2.4M | -$2.1M |
| Net income | -$1.3M | -$2.4M | -$2.8M | -$2.0M | -$1.6M | -$2.3M | -$2.4M | -$2.1M |
| Diluted EPS | -$0.17 | -$0.23 | -$0.29 | -$0.15 | -$0.10 | -$0.13 | -$0.12 | -$0.11 |
| Operating cash flow | -$1.2M | -$800,210.00 | -$1.1M | -$1.4M | -$917,165.00 | -$1.5M | -$1.1M | -$1.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 73.0% | 64.8% | 72.4% | 66.9% | 67.6% | 78.2% | 87.8% | 87.8% |
| Operating margin | -4832.4% | -6962.1% | -10579.5% | -4903.6% | -2296.2% | -12924.3% | -1403.9% | -14179.9% |
| Net margin | -4785.7% | -6794.9% | -10424.5% | -4847.8% | -2239.7% | -12542.3% | -1382.6% | -14025.7% |
Company news
Jun 10, 2026
- 40d agoNexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.finance.yahoo.com
- 40d agoEXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Lifefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-29 | OSSER LEONARD | Award | 83,333 | $0.00 | $0.00 | filing |
| 2025-09-29 | Owens David· Chief Medical Officer | Award | 36,459 | $0.00 | $0.00 | filing |
| 2025-09-29 | Hu Ben | Award | 36,459 | $0.00 | $0.00 | filing |
| 2025-09-29 | Kazden Alan | Award | 36,459 | $0.00 | $0.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.